Merck’s KEYTRUDA® (pembrolizumab) receives two new approvals in Japan
KEYTRUDA Now Approved for Patients With PD-L1-Positive Esophageal Squamous Cell Carcinoma Who Have Progressed After Chemotherapy and for a Six-Week Dosing Schedule Across All Adult Indications Six-Week Dosing Schedule for KEYTRUDA Now Approved in Japan, US and Europe KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck